Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Juvéderm VOLIFT + lidocaine is a **sterile, cross-linked hyaluronic acid gel** combined with **lidocaine** (a local anaesthetic), intended for **injection into the deep dermis or lips mucosa** for the treatment of **moderate to deep facial wrinkles, folds (e.g., nasolabial and mentolabial folds), contouring, and volume loss** (including lips, forehead, jawline, temple, malar area, and eyebrow)[1][5]. The **hyaluronic acid** functions as a dermal filler to restore volume and smooth skin depressions by physically integrating into the tissue, providing hydration and mechanical support[1][2][3][5]. **Lidocaine** is included to minimize pain and discomfort during the injection procedure[1][5]. Developed using Allergan's **Vycross cross-linking technology** for enhanced smoothness, stability, and relatively long-lasting effects (typically up to 15–18 months)[2][3]. **Primary indications**: treatment of moderate to severe facial wrinkles/facial folds and facial volume restoration[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Juvéderm VOLIFT + lidocaine.